Investigating the role of glutaredoxin and glutathione in lung cancer
Official title: Glutaredoxin, Glutathione Metabolism and Lung Cancer
Funded at University of Vermont & St Agric College · NIH-11139436 · Data updated 2026-11-12
This study is looking at how a substance called glutathione, which helps protect our cells, is connected to lung cancer, especially in patients with a specific gene change, and it hopes to find new ways to improve treatment for those affected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Vermont & St Agric College NIH-funded |
| Lab location | 1 site (Burlington, United States) |
| Project start | May 10, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $528,642 |
| NIH project number | 5R01CA273238-03 |
| Project ID | NIH-11139436 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with KRAS-mutant lung adenocarcinoma.
✕Less likely to help
Patients with lung cancer that does not involve KRAS mutations may not benefit from this research.
What this research studies
This research focuses on understanding how glutathione, an important antioxidant, is involved in lung cancer, particularly in cases with KRAS mutations. The study examines the role of glutaredoxin, an enzyme that regulates glutathione levels and redox signaling, and how its disruption may contribute to lung adenocarcinoma. By analyzing protein modifications and cellular mechanisms, the research aims to uncover potential therapeutic targets for improving lung cancer treatment.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for treating lung cancer by targeting the glutaredoxin and glutathione pathways.
How similar studies have gone: Other research has shown promising results in targeting redox signaling pathways in cancer, suggesting that this approach may be viable.
Where this research is happening
-
University of Vermont & St Agric College
Burlington, United States Active
Researchers
- Principal investigator: Janssen-Heininger, Yvonne M. W. — University of Vermont & St Agric College
- Study coordinator: Janssen-Heininger, Yvonne M. W.
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.